A Phase I Trial of Pox PSA vaccines (PROSTVAC<sup>®</sup>-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer
<p>Abstract</p> <p>Purpose</p> <p>Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA) targeted therapeutic vaccines, as well as recent laboratory data supporting the value of the addition of...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-01-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://www.translational-medicine.com/content/4/1/1 |
id |
doaj-a916471698e74b47be6ee130e3f7e7af |
---|---|
record_format |
Article |
spelling |
doaj-a916471698e74b47be6ee130e3f7e7af2020-11-24T21:27:00ZengBMCJournal of Translational Medicine1479-58762006-01-0141110.1186/1479-5876-4-1A Phase I Trial of Pox PSA vaccines (PROSTVAC<sup>®</sup>-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate CancerLattime EIsraeli RPetrylak DPKaufman HPlante MDiPaola RSManson KSchuetz T<p>Abstract</p> <p>Purpose</p> <p>Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA) targeted therapeutic vaccines, as well as recent laboratory data supporting the value of the addition of co-stimulatory molecules B7-1, ICAM-1, and LFA-3 (designated TRICOM™) to these vaccines, we conducted a Phase I study to evaluate the safety and immunogenicity of a novel vaccinia and fowlpox vaccine incorporating the PSA gene sequence and TRICOM.</p> <p>Methods</p> <p>In this study, ten patients with androgen independent prostate cancer with or without metastatic disease were enrolled. Patients were treated with 2 × l0<sup>8 </sup>pfu of a recombinant vaccinia virus vaccine (PROSTVAC-V) followed by 1 × 10<sup>9 </sup>pfu of the booster recombinant fowlpox virus (PROSTVAC-F) both with gene sequences for PSA and TRICOM. The mean age of patients enrolled in the study was 70 (range 63 to 79). The mean PSA at baseline was 434 (range 9 – 1424).</p> <p>Results</p> <p>There were no deaths, and no Grade 3 or 4 adverse events. The most commonly reported adverse events, regardless of causality, were injection site reactions and fatigue. One serious adverse event (SAE) occurred that was unrelated to vaccine; this patient developed progressive disease with a new sphenoid metastasis. PSA was measured at week 4 and week 8. Four patients had stable disease (with less than 25% increase in PSA) through the week 8 study period. Anti-PSA antibodies were not induced with therapy: however, anti-vaccinia titers increased in all patients.</p> <p>Conclusion</p> <p>This study demonstrated that vaccination with PROSTVAC-V and PROSTVAC-F combined with TRICOM is well-tolerated and generated an immune response to vaccinia. Therefore, PROSTVAC-VF/TRICOM represents a feasible therapeutic approach for further phase II and III study in patients with prostate cancer.</p> http://www.translational-medicine.com/content/4/1/1PSAProstate specific antigenvaccineco-stimulatory molecules |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lattime E Israeli R Petrylak DP Kaufman H Plante M DiPaola RS Manson K Schuetz T |
spellingShingle |
Lattime E Israeli R Petrylak DP Kaufman H Plante M DiPaola RS Manson K Schuetz T A Phase I Trial of Pox PSA vaccines (PROSTVAC<sup>®</sup>-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer Journal of Translational Medicine PSA Prostate specific antigen vaccine co-stimulatory molecules |
author_facet |
Lattime E Israeli R Petrylak DP Kaufman H Plante M DiPaola RS Manson K Schuetz T |
author_sort |
Lattime E |
title |
A Phase I Trial of Pox PSA vaccines (PROSTVAC<sup>®</sup>-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer |
title_short |
A Phase I Trial of Pox PSA vaccines (PROSTVAC<sup>®</sup>-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer |
title_full |
A Phase I Trial of Pox PSA vaccines (PROSTVAC<sup>®</sup>-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer |
title_fullStr |
A Phase I Trial of Pox PSA vaccines (PROSTVAC<sup>®</sup>-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer |
title_full_unstemmed |
A Phase I Trial of Pox PSA vaccines (PROSTVAC<sup>®</sup>-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer |
title_sort |
phase i trial of pox psa vaccines (prostvac<sup>®</sup>-vf) with b7-1, icam-1, and lfa-3 co-stimulatory molecules (tricom™) in patients with prostate cancer |
publisher |
BMC |
series |
Journal of Translational Medicine |
issn |
1479-5876 |
publishDate |
2006-01-01 |
description |
<p>Abstract</p> <p>Purpose</p> <p>Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA) targeted therapeutic vaccines, as well as recent laboratory data supporting the value of the addition of co-stimulatory molecules B7-1, ICAM-1, and LFA-3 (designated TRICOM™) to these vaccines, we conducted a Phase I study to evaluate the safety and immunogenicity of a novel vaccinia and fowlpox vaccine incorporating the PSA gene sequence and TRICOM.</p> <p>Methods</p> <p>In this study, ten patients with androgen independent prostate cancer with or without metastatic disease were enrolled. Patients were treated with 2 × l0<sup>8 </sup>pfu of a recombinant vaccinia virus vaccine (PROSTVAC-V) followed by 1 × 10<sup>9 </sup>pfu of the booster recombinant fowlpox virus (PROSTVAC-F) both with gene sequences for PSA and TRICOM. The mean age of patients enrolled in the study was 70 (range 63 to 79). The mean PSA at baseline was 434 (range 9 – 1424).</p> <p>Results</p> <p>There were no deaths, and no Grade 3 or 4 adverse events. The most commonly reported adverse events, regardless of causality, were injection site reactions and fatigue. One serious adverse event (SAE) occurred that was unrelated to vaccine; this patient developed progressive disease with a new sphenoid metastasis. PSA was measured at week 4 and week 8. Four patients had stable disease (with less than 25% increase in PSA) through the week 8 study period. Anti-PSA antibodies were not induced with therapy: however, anti-vaccinia titers increased in all patients.</p> <p>Conclusion</p> <p>This study demonstrated that vaccination with PROSTVAC-V and PROSTVAC-F combined with TRICOM is well-tolerated and generated an immune response to vaccinia. Therefore, PROSTVAC-VF/TRICOM represents a feasible therapeutic approach for further phase II and III study in patients with prostate cancer.</p> |
topic |
PSA Prostate specific antigen vaccine co-stimulatory molecules |
url |
http://www.translational-medicine.com/content/4/1/1 |
work_keys_str_mv |
AT lattimee aphaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT israelir aphaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT petrylakdp aphaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT kaufmanh aphaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT plantem aphaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT dipaolars aphaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT mansonk aphaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT schuetzt aphaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT lattimee phaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT israelir phaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT petrylakdp phaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT kaufmanh phaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT plantem phaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT dipaolars phaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT mansonk phaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer AT schuetzt phaseitrialofpoxpsavaccinesprostvacsupsupvfwithb71icam1andlfa3costimulatorymoleculestricominpatientswithprostatecancer |
_version_ |
1725977019170160640 |